ZEB2 and acute myeloid leukemia: Knock-down of ZEB2 in human AML cell lines resulted in enhanced morphological differentiation as assayed by May–Grunwald–Giemsa staining analysis and increased mature CD11B myeloid marker expression in flow cytometry analysis [139].